An interventional study of Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste) and CPC Mouthwash (Parodontax Active Gum Health Mouthwash) in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by HALEON · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Dental Plaque with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Dental Plaque · United States.
Among the 65 studies in Dental Plaque with a site in United States, this one is the 8th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2024, is one of 33 with no phase, and was the 51st registered.
352 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.
Browse Dental Plaque studies →7 of the 65 studies in Dental Plaque with a site in United States are open now. Recruiting first, the newest first:
Flaus, Inc · Sites in United States
Ages 18–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–70
Lactea Therapeutics, LLC · Sites in United States
Ages 18–65 · Healthy volunteers
University of Nebraska · Sites in United States
Ages 19–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Dental Plaque studies recruiting now, 10 (29%) set no upper age limit and 20 (57%) stop at 75 or younger; 14 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 12 · Phase 4 4
First in 1998; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 56 across 316 interventional studies indexed under Dental Plaque.
Median enrollment 80 across the 59 interventional studies, 122 across the 6 observational. Of the 57 that completed or were terminated, 26 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 65 have an industry lead sponsor. The 10 most frequent:
HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
HALEON has 9 studies filed under Dental Plaque — fewer than ten, so there is no comparison to draw.
3 of the studies in Dental Plaque with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07605338Phase 3Colgate PalmoliveTo Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. | 2026-11 |
| NCT07706647The University of Texas Health Science Center at San AntonioOil Pulling Reduction | 2026-11-30 |
| NCT05384132University of Alabama at BirminghamNovel Dental Gel as an Adjunct to Scaling and Root Planing | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies in Dental Plaque with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the ability of a marketed Cetylpyridinium Chloride (CPC) mouthwash alongside a marketed Stannous Fluoride (SnF2) toothpaste in improving gingival health and reducing plaque accumulation, compared to the use of a regular fluoride toothpaste alone in participants with clinically measurable plaque-induced gingivitis.
This will be a single center, 12-week, randomized, controlled, examiner-blind, 3-treatment arm, parallel group, stratified (by sex [male/female]) study to evaluate the efficacy of using the SnF2 toothpaste/CPC mouthwash twice daily in reducing gingivitis and plaque accumulation in a population with clinically measurable levels of gingivitis. The clinical efficacy of the commercially available SnF2 toothpaste/CPC mouthwash will be compared with that of a commercially available, regular fluoride toothpaste with no known anti-gingivitis nor anti-plaque efficacy properties (negative control). This study will also explore whether a CPC mouthwash used with a SnF2 toothpaste could provide benefits in plaque accumulation reduction and gingival health improvement over the sole use of SnF2 toothpaste (reference product). Sufficient participants will be screened to randomize approximately 198 participants (approximately 66 per group) to ensure approximately 180 evaluable participants (approximately 60 per group) complete the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
AT SCREENING (Visit 1):
AT BASELINE (Visit 2; Prior to Dental Prophylaxis):
Exclusion Criteria:
Medication exclusions: At screening (Visit 1):
Medication exclusions: At Baseline (Visit 2):
Periodontal exclusions:
Dental Exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will brush their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants will swish 20 milliliters (mL) of the mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.
Drug: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste) · Drug: CPC Mouthwash (Parodontax Active Gum Health Mouthwash)
Participants will brush their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
Drug: Regular Fluoride Toothpaste (Crest Cavity Protection)
Participants will brush their teeth with full ribbon of reference toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.
Drug: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)
Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.
Mouthwash containing 0.07% w/w CPC.
Toothpaste containing 0.243% w/w sodium fluoride.
Toothpaste containing 0.454% w/w SnF2.
Overall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste)
Gingival bleeding was assessed according to the expanded bleeding index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Time frame: Week 12
Interproximal NBS at Week 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Time frame: Week 12
Overall NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Time frame: Week 6
Interproximal NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Time frame: Week 6
Mean Overall Bleeding Index (Bl) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Interproximal BI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Overall Modified Gingival Index (MGI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Interproximal MGI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Overall Turesky Plaque Index (TPI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/ palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 millimeter\[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<)1/3 of the tooth surface, 4= Plaque covering greater than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Interproximal TPI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Overall NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Time frame: Week 6 and Week 12
Interproximal NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
Time frame: Week 6 and Week 12
Mean Overall BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Interproximal BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Overall MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Interproximal MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Overall TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores was recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
Mean Interproximal TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
Time frame: Week 6 and Week 12
This study was conducted at a single center in United States of America.
| Milestone | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|---|
| Started | 65 | 65 | 66 |
| Completed | 63 | 61 | 59 |
| Not completed | 2 | 4 | 7 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 7 |
Gingival bleeding was assessed according to the expanded bleeding index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
| bleeding sites | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Overall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste) | 10.1 ± 1.03 | 24.1 ± 1.05 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
| bleeding sites | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Interproximal NBS at Week 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste) | 4.5 ± 0.72 | 15.0 ± 0.74 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
| bleeding sites | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Overall NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste) | 10.6 ± 1.09 | 25.0 ± 1.09 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
| bleeding sites | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Interproximal NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste) | 5.1 ± 0.76 | 15.4 ± 0.76 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
| score on a scale | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 0.08 ± 0.009 | 0.20 ± 0.009 |
| Week 12 | 0.08 ± 0.009 | 0.19 ± 0.009 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
| score on a scale | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 0.06 ± 0.009 | 0.18 ± 0.009 |
| Week 12 | 0.05 ± 0.009 | 0.17 ± 0.009 |
The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
| score on a scale | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 0.93 ± 0.032 | 1.43 ± 0.032 |
| Week 12 | 0.78 ± 0.027 | 1.31 ± 0.027 |
The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
| score on a scale | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 1.13 ± 0.033 | 1.62 ± 0.033 |
| Week 12 | 0.97 ± 0.027 | 1.49 ± 0.028 |
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/ palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 millimeter\[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<)1/3 of the tooth surface, 4= Plaque covering greater than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
| score on a scale | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 2.59 ± 0.045 | 2.95 ± 0.046 |
| Week 12 | 2.38 ± 0.052 | 2.83 ± 0.054 |
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
| score on a scale | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 2.88 ± 0.040 | 3.19 ± 0.041 |
| Week 12 | 2.69 ± 0.048 | 3.10 ± 0.049 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
| bleeding sites | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 14.1 ± 1.09 | 25.0 ± 1.09 |
| Week 12 | 11.4 ± 1.04 | 24.1 ± 1.05 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.
| bleeding sites | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 7.8 ± 0.76 | 15.4 ± 0.76 |
| Week 12 | 6.1 ± 0.73 | 15.0 ± 0.74 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
| score on a scale | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 0.11 ± 0.009 | 0.20 ± 0.009 |
| Week 12 | 0.08 ± 0.009 | 0.19 ± 0.009 |
Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.
| score on a scale | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 0.09 ± 0.009 | 0.18 ± 0.009 |
| Week 12 | 0.06 ± 0.009 | 0.17 ± 0.009 |
The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
| score on a scale | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 1.11 ± 0.032 | 1.43 ± 0.032 |
| Week 12 | 0.88 ± 0.027 | 1.31 ± 0.027 |
The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.
| score on a scale | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 1.31 ± 0.032 | 1.62 ± 0.033 |
| Week 12 | 1.06 ± 0.027 | 1.49 ± 0.028 |
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores was recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
| score on a scale | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 2.88 ± 0.045 | 2.95 ± 0.046 |
| Week 12 | 2.74 ± 0.053 | 2.83 ± 0.054 |
The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.
| score on a scale | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|
| Week 6 | 3.15 ± 0.040 | 3.19 ± 0.041 |
| Week 12 | 3.02 ± 0.049 | 3.10 ± 0.049 |
Collected over Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | 0/65 (0%) | 0/65 (0%) | 19/65 (29.2%) |
| Reference Toothpaste (SnF2 Toothpaste) | 0/65 (0%) | 0/65 (0%) | 6/65 (9.2%) |
| Negative Control Toothpaste (Sodium Fluoride Toothpaste) | 0/66 (0%) | 0/66 (0%) | 2/66 (3%) |
| Event | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) |
|---|---|---|---|
| Tooth DiscolourationGastrointestinal disorders | 14/65 | 1/65 | 0/66 |
| Aphthous UlcerGastrointestinal disorders | 2/65 | 2/65 | 0/66 |
| Oral Mucosal ExfoliationGastrointestinal disorders | 2/65 | 1/65 | 1/66 |
| Tongue CoatedGastrointestinal disorders | 2/65 | 1/65 | 0/66 |
| Coronavirus Test PositiveInvestigations | 0/65 | 1/65 | 0/66 |
| Taste DisorderNervous system disorders | 1/65 | 0/65 | 0/66 |
| SinusitisInfections and infestations | 0/65 | 0/65 | 1/66 |
Safety population- comprised all randomized participants who received at least one dose of investigational product.
| Age, Continuous(years) | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) | Total |
|---|---|---|---|---|
| Mean | 51.8 ± 14.36 | 47.6 ± 14.32 | 50.7 ± 13.38 | 50.1 ± 14.06 |
| Sex: Female, Male(Participants) | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) | Total |
|---|---|---|---|---|
| Female | 55 | 55 | 54 | 164 |
| Male | 10 | 10 | 12 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 4 | 12 |
| Not Hispanic or Latino | 61 | 61 | 62 | 184 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) | Reference Toothpaste (SnF2 Toothpaste) | Negative Control Toothpaste (Sodium Fluoride Toothpaste) | Total |
|---|---|---|---|---|
| African American/African Heritage | 4 | 6 | 6 | 16 |
| American Indian or Alaskan Native | 0 | 0 | 1 | 1 |
| Asian - South East Asian Heritage | 1 | 0 | 0 | 1 |
| White - Arabic/North African Heritage | 4 | 2 | 4 | 10 |
| White - White/Caucasian/European Heritage | 55 | 57 | 54 | 166 |
| Multiple | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trialregister@haleon.com.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
Ran from Nov 2024 to primary completion in Mar 2025, 3 months.
Results were first posted in Mar 2026, 1 year after primary completion.
Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.
Counting every sponsor, half of 178 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.